These studies suggest that the therapeutic strategy of AMPK activation may be applicable not only to mitochondrial disease, but a broad spectrum of disorders with secondary mitochondrial dysfunction including age-related macular degeneration. This evidence concerns the gene PRKAA1 and age-related macular degeneration.